ARCH Venture, a provider of seed and early stage venture capital, led a $130m Series B funding round in Be Bio, a deverloper of B cells medicines designed to unleash the potential of cell therapies in applications beyond cytotoxicity, with participation from Bristol Myers Squibb, Atlas Venture, RA Capital Management, Alta Partners, Longwood Fund and Takeda Ventures. The proceeds will advance Be Bio’s proprietary autologous and allogeneic BeCM platforms across multiple therapeutic areas and progress pipeline candidates toward the clinic. “Our pipeline spans multiple therapeutic areas, and we are inspired and humbled by the potential to transform patients’ lives. With the support of highly regarded investors and the addition of Dr. Gillis to our Board of Directors, Be Bio is in a strong position to advance novel programs across our rare disease and oncology portfolios, further develop our platform and manufacturing capabilities and expand our team," Joanne Smith-Farrell, Be Bio CEO.